Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | METAP1 | P53582 | 2/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15701683 | 0.90 | OPRM1 (0.46) | HRH3KCNH2OPRM1OPRL1CXCR4 | |
| SCHEMBL15701689 | 0.90 | OPRM1 (0.46) | HRH3KCNH2OPRM1OPRL1CXCR4 | |
| SCHEMBL15701680 | 0.87 | OPRM1 (0.42) | KCNH2OPRM1OPRL1LMNACXCR4 | |
| SCHEMBL15701681 | 0.86 | OPRM1 (0.41) | HRH3KCNH2OPRM1OPRL1SIGMAR1 | |
| SCHEMBL15701686 | 0.85 | OPRM1 (0.43) | HRH3KCNH2OPRM1OPRL1LMNA | |
| SCHEMBL14149844 | 0.80 | OPRM1 (0.64) | HRH3KCNH2OPRM1OPRL1LMNA | |
| SCHEMBL15703866 | 0.80 | OPRM1 (0.64) | HRH3KCNH2OPRM1OPRL1LMNA | |
| SCHEMBL13587827 | 0.80 | CXCR4 (0.41) | HRH3KCNH2OPRM1OPRL1CXCR4 | |
| SCHEMBL14558528 | 0.78 | CXCR4 (0.40) | HRH3KCNH2OPRM1CXCR4 | |
| SCHEMBL7309721 | 0.78 | CXCR4 (0.40) | HRH3KCNH2OPRM1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | HRH3 4398/4885KCNH2 1587/4885OPRM1 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.